Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
7 years old? Seriously?
How about these as counter.........
from today:
https://seekingalpha.com/article/4576726-anavex-life-sciences-q1-earnings-reveals-strong-cash-position?mailingid=30504898&messageid=must_reads&serial=30504898.2443926&utm_campaign=Must%2BReads%2BFebruary%2B9%2C%2B2023&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads
and also today:
https://finance.yahoo.com/m/300043d5-056e-31f1-92cf-1ef2b03e2ec2/this-short-squeeze-candidate.html
Sweetheart deal for Lincoln looks desperate and rushed.
Fifteen to twenty percent haircut coming to price in full dilution.
OK - We're Down 2 Days in a row right after signing the LPC deal. Anyone still think it was a good idea?
Our stock had just gone up $ .80 the day before. Come on guys - admit this looks bad! Please don't tell me the XBI was down or even SAVA - BS. ANVS was still up. That should be us, but it's not! Someone made a good point on the Stocktwits - that maybe Missling doesn't have the goods and they know it - beginning to wonder. We need some news SOON! .
sab, at some point hedge funds that have had a short position usually realize that the downside no longer exists as it once did. I think we are past that point and I think many hedge funds have realized it or will shortly make a decision consistent with that viewpoint.
Fitzy, if this is your first pre-commercial life sciences investment then there is nothing wrong with that but you have to do some of your own research to make lessons like this stick.
8 years ago they had 52m shares outstanding - so still pretty spectacular management of resources to get here with only 20m additional shares being issued.
The false narrative you and others try to spread here doesn't stand up to scrutiny.
Did u read it?
It talks about other financing deals and effect on share price
"Someone on stocktwits posted this"
Apr. 26, 2016 10:00 AM ET
Someone on stocktwits posted this—psnml
https://seekingalpha.com/article/3967979-anavex-life-sciences-miracle-drug-toxic-financing-set-for-severe-decline-in-price
I don’t think they can short but its not a good track record
This is an old article…but any comnents to the contrary would be appreciated
These types of attacks are not helpful.
What does one’s career have to do with ability to post things? What do you do? Are all the bulls scientists? Please refrain from ad hominem attacks
Why not address elephant in the room…
Lack of data for endpoints, lack of stock interest by institutions, lack of transparency with management?
How about talking about verifiable facts instead?
I don’t disagree..
Just saying the chart isn’t bad…its the p values lol
Everyone knows the answer. EOT is not significant for either Rett or AD (RSBQ, ADAS-Cog, ADL). So RSBQ-AUC and ODDS ratios with artificially chosen thresholds were invented to generate p-values.
Those are facts.
This is not bad imo if you include all comers
But also you sava comparison is not accurate imo (or whomever did charting) it is certainly not placebo
The problem is just whether p value really show significance and not for odds ratio
Has anyone noticed that when the short interest goes up BIG, the stock price goes UP?
However when it goes down, the stock price has gone down?
Let's hope the price is able to stay above the 200 day by the close or at least bounce at the lower 50 day....
At least Friday's are sometimes good to $AVXL
This stock travels in mysterious ways and certainly, up to now, does not have lasting momentum....
Buona Sera!
:)
Yes, but contrast that with the 2nd half of December, in which the short interest increased even though the share price was below 9 almost the entire time, especially since the first half of December would have been a much better time to establish a new short position (or add to an existing one).
I don't get what you mean by "SHORT is adjusted price," though I agree short positions commonly are covered and reestablished rather than "buy and hold."
Do you find it meaningless that the short position shrank by more than it had in the past year (indeed by much more than for any period but one).
IF you want an example of poor Corporate communication...
Take a look at Lyft today.
What makes you so sure that CM won’t switch to AUC again? Eg, right before data release ….
Gotta love the AH 10.66 print.
Idiot......$50
yes, I saw 16.78 mil....down about 9%
https://www.wsj.com/market-data/quotes/AVXL
MOST don't realize that SHORT is adjusted price perhaps MUCH more than buy and hold.
Those claiming to accumulate facilitate that rotation.
I defy proof that a short @ 31 still has not covered.
Hell, I bet a short @ $10 covered below $8.
Sorry, but my confusion continues. Without orphan status or some special situation (like Covid arguably presented), wouldn't the FDA (or patent protection) preclude generics for a specified number of years anyway?
(I appreciate this group effort that's educating me!)
Short interest hasn't dropped so much in the last year.
Exclusivity refers to FDA authorization of a generic form of the drug. It does not refer to other drugs that treat the same indication.
Our FDA has been grasping at straws ... any straws because it's been desperate to find a drug or, a process that works. Unfortunately, in over 38 years concerning any drug company that focused exclusively on the plaque or, the tau has been unsuccessful. This includes the 2 Biogen drugs. The first one, Aduhelm never, ever should have been approved by the FDA. In over 6 years of Biogen testing it, the drug repeatedly kept failing it's testing to costing Biogen $6 - 7 Billion. The drug caused the patients brains to bleed and patients to die.
Biogen's 2nd drug with Elsai has the same focus and the results are pretty much the same with brain bleeds and AD patients again dying. Their approach does not work !!! They are treating a symptom of the disease but, not the disease itself, which many, many areas and our FDA does not understand ... and it's killing AD patients. This treatment does not work
Anavex has a solution with it's drug blarcamesine. Hopefully, an article gets published in a medical journal and Anavex meets with this FDA to discuss approval ... accelerated approval as soon as possible because lives and families will benefit and depend on this approach !!!
Nope...it will just take the wind out of Anavex's "sales"...
According to Stock analysis AVXL is #84 on the XBI holdings list as of Feb 6 2023.
New Short Interest is Down:
01/31/2023 16,719,384 (8.98) 1,128,968 14.81
01/13/2023 18,368,256 0.63 1,504,154 12.21
12/30/2022 18,252,546 15.66 1,422,909 12.83
12/15/2022 15,780,885 32.45 7,073,260 2.23
11/30/2022 11,914,762 17.19 1,787,726 6.66
11/15/2022 10,167,456 0.61 986,389 10.31
10/31/2022 10,105,713 0.62 985,598 10.25
10/14/2022 10,043,451 (2.12) 718,819 13.97
09/30/2022 10,260,594 5.37 936,366 10.96
09/15/2022 9,737,900 6.97 683,304 14.25
A little over 16 million.
In the REAL WORLD we are a dying breed with accountability.
Short Interest tonight at 4 pm.............oh boy
Given the VWAP MOC will be close to the day's low.
No TARDIS needed as still awaiting a re entry price.
ConfirmationBiasSuxs posted this on ST around 2:00pm today.
"Some shorts got out! report says on 1-31-23... 16,719,384 shares were short.... 22.11% Still some ammo for a squeeze... but the sexiness is dropping... Good for us either way... the remaining shorts are gonna start second guessing themselves."
Some could reattach based on how they skew the new financing deal but the run up prior to the earnings call was definitely shaking some of them loose.
Only a few posts left for me today:
200 Day hits at 10.21 and it looks like that is the best we can expect for now....Leo your outlook which you openly mentioned is again very good
9.71 to 11 was the good trade.
I'm positive we will hear better.
Where will the Market take AVXL for re entry?
Doesn't a patent, without orphan status, preclude generics?
Is the difference that you're using a broader definition of "generic" in this context? Like a competitor on a patented drug could develop and market a different formulation that still has the same mode of action but couldn't do that if the drug had orphan status?
Thanks for the on-point reply. (I wish I understood it better!)
The problem with math is GIGO.
The answer to this is very simple. Have a company present a drug or treatment that slows the decline or improves the functioning of AD patients that does not attack AD via amyloid.
So far the FDA hasn't seen such a drug or treatment.
I wonder what company will be the first to do that?
Can anybody explain what is going on w/the SP today ? Why down? What is being said/done to cause what we are seeing? AGAIN...???We should at least be stable-flat...IMO.
Are the AHs still trying to scare people? who posts as frequently as these MFrs unless they have an agenda?
Approval of trofenide will NOT delay the approval of Anavex’s blarcamesine according to FDA rules.
GOD bless,
Orphan drugs get 7 years of exclusivity and typical new drugs get only 5 years. Exclusivity does not prevent marketing of a new chemical entity for the orphan disease but rather a generic with the same active moiety. So the FDA's action on trofinetide has no bearing on the regulatory approval of blarcamesine. Though regulatory exclusivity is 7 years for Rett (and other orphan diseases), for AD or PDD, it would only be 5 years. However, patents listed in the Orange book associated with the approval of a drug can extend the commercial exclusivity (commercial exclusivity is the longer of regulatory and legal exclusivity). Patents not listed in the Orange book can usually be litigated away so seldom prolong the exclusivity.
Wow...at the center of the cabal...
why hurry ?
Time is your friend and you will have a lot of 'friend'
Followers
|
1074
|
Posters
|
|
Posts (Today)
|
46
|
Posts (Total)
|
463672
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |